ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Multimedia
    • Video
    • Audio
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

SM12: Otolaryngologists Debate Resident Training, Implantable Hearing Aids, Oropharyngeal Cancer

by Thomas R. Collins • February 14, 2012

  • Tweet
  • Email
Print-Friendly Version

The Esteem is totally implantable, removing the social stigma of a visible device.

You Might Also Like

  • HPV Status an Independent Prognostic Factor for Oropharyngeal Cancer Survival
  • SM12: Options for Hearing Loss are Multiplying
  • SM14: Treatment for Thyroid Tumors and Benefits of Hearing Devices Spark Debate Among Otolaryngologists
  • Thinking of Adding Hearing Aids to Your Practice? Experts Dispense Advice
Explore This Issue
February 2012

“The technology really has matured to the point where it’s a reasonable alternative,” Dr. Arriaga said. “The outcomes really are quite positive in the majority of patients,” he said. “It really does seem like a reasonable option for an unsatisfied hearing aid user.”

Peter Weisskopf, MD, FACS, head of the neurotology section at the Barrow Neurological Institute in Phoenix, Ariz., argued that what is left unsaid in marketing materials is that 44 percent of Esteem users had WRS scores worse than or equal to their hearing with a hearing aid, according to manufacturer Envoy Medical’s own published results, posted on envoymedical.com.

He called into question the ethics involved in the use of the devices, noting that companies spend up to $10 million a year on advertising, that patients’ first point of contact is the company itself and that implants are done on a cash basis.

“Can you get a second opinion? Is there a second opinion?” he said. “I don’t feel qualified to give one. I haven’t been trained by the Esteem company to tell what all the pros and cons are. So what is a patient to do?”

He also said there was an inherent bias at the centers that did the research leading to approvals, because the research was supported by the manufacturer. With little long-term data available, a cost that can reach $30,000 and the risk of a surgical procedure, he said, “Why take the risk?”

Managing Oropharyngeal Cancer

Randal Weber, MD, FACS, chair of head and neck surgery at the University of Texas M.D. Anderson Cancer Center in Houston, argued for a non-surgical approach to oropharyngeal cancer.

Among the data he cited were 102 patients at his own center who received unilateral irradiation for T1 and T2 tonsil cancer, with a five-year locoregional control rate of 100 percent, 95 percent overall survival and excellent functional outcome with no patients requiring a long-term G-tube or tracheostomy.

A 2006 study (N Engl J Med. 354;6) found that radiotherapy plus Cetuximab was superior to radiation alone for locoregionally advanced squamous cell carcinoma of the head and neck, resulting in 49 months of locoregional control among those with oropharyngeal cancer, he noted.

But he also said a non-surgical approach might not be best for those with high-risk oropharyngeal tumors, defined by T4 tumors and advanced neck disease, and for HPV-negative tumors, based on the RTOG 0129 trial recently published in the New England Journal of Medicine.

Pages: 1 2 3 4 | Single Page

Filed Under: Features Tagged With: Combined Sections Meeting, CSM, endoscopic surgery, Hearing aids, hearing loss, hours, implantable devices, oropharyngeal cancer, staffing, Zenker's diverticulumIssue: February 2012

You Might Also Like:

  • HPV Status an Independent Prognostic Factor for Oropharyngeal Cancer Survival
  • SM12: Options for Hearing Loss are Multiplying
  • SM14: Treatment for Thyroid Tumors and Benefits of Hearing Devices Spark Debate Among Otolaryngologists
  • Thinking of Adding Hearing Aids to Your Practice? Experts Dispense Advice

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Is There a Crisis in the Otolaryngology Match?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Post-Tonsillectomy Taste Disorders Rare but Present
    • Study: Artificial Intelligence Can Help Predict Risk of Thyroid Cancer on Ultrasound
    • Nobel Awards for Otolaryngology Research
    • Visual Abstract Competition to Launch at 2020 Triological Society Sections Meeting
    • More Severe OSA Leads to Higher Blood Pressure in Patients with Resistant Hypertension
    • Link Between Hearing and Cognition Begins Earlier Than Once Thought

Polls

Will registry information and data science improve patient care?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2019 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.